DEFB130A: A Potential Drug Target and Biomarker (G245940)

Target Name: DEFB130A

NCBI ID: G245940

DEFB130A

DEFB130A: A Potential Drug Target and Biomarker

DEFB130A is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the Defensin family of proteins, which are involved in cellular defense and inflammation. DEFB130A has been shown to play a role in the regulation of inflammation and immune responses, and is potential drug target.

Purpose of the Article

The purpose of this article is to provide an overview of DEFB130A as a drug target and biomarker. We will discuss the DEFB130A protein, its function in cellular defense and inflammation, and the potential for it to be used as a drug target.

An Overview of DEFB130A

DEFB130A is a 21-kDa protein that is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the Defensin family of proteins, which are involved in cellular defense and inflammation. DEFB130A is composed of two major domains: an N-terminal transmembrane domain and a C-terminal cytoplasmic domain.

DEFB130A has been shown to play a role in the regulation of inflammation and immune responses. It is involved in the development and maintenance of theMannan-binding lectin (MBL) system, which is a natural defense mechanism against pathogens and is expressed in various tissues of the body. The MBL system is involved in the regulation of inflammation and immune responses by activating the downstream signaling cascade, which includes the production of pro-inflammatory cytokines and the recruitment of immune cells to the site of infection or inflammation.

In addition to its role in the MBL system, DEFB130A has also been shown to be involved in the regulation of cell survival and apoptosis. It has been shown to promote the survival of cancer cells and to contribute to the development of cancer. DEFB130A has also been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway.

Potential Drug Target

The potential for DEFB130A as a drug target is based on its involvement in the regulation of inflammation and immune responses, as well as its role in the regulation of cell survival and apoptosis.

One potential mechanism by which DEFB130A could be targeted as a drug is its role in the regulation of the MBL system. The MBL system is involved in the regulation of inflammation and immune responses by activating the downstream signaling cascade, which includes the production of pro-inflammatory cytokines and the recruitment of immune cells to the site of infection or inflammation. By inhibiting the activity of DEFB130A, it may be possible to reduce the production of pro-inflammatory cytokines and the recruitment of immune cells to the site of infection or inflammation, leading to reduced inflammation and improved immune function.

Another potential mechanism by which DEFB130A could be targeted as a drug is its role in the regulation of cell survival and apoptosis. As mentioned earlier, DEFB130A has been shown to promote the survival of cancer cells and to contribute to the development of cancer. By inhibiting the activity of DEFB130A, it may be possible to inhibit the survival of cancer cells and reduce the development of cancer.

In addition to its potential as a drug target, DEFB130A is also a potential biomarker for the diagnosis and prognosis of various diseases, including cancer. Its involvement in the regulation of inflammation and immune responses, as well as its role in the regulation of cell survival and apoptosis, make it an attractive candidate for

Protein Name: Defensin Beta 130A

The "DEFB130A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFB130A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets